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Tumor suppressorSirtuins (SIRT1–7), the mammalian homologues of the Sir2 gene in yeast, have emerging roles in age-related
diseases, such as cardiac hypertrophy, diabetes, obesity, and cancer. However, the role of several sirtuin family
members, including SIRT1 and SIRT3, in cancer has been controversial. The aim of this review is to explore and
discuss the seemingly dichotomous role of SIRT3 in cancer biology with particular emphasis on its potential
role as a tumor promoter and tumor suppressor. This review will also discuss the potential role of SIRT3 as a
novel therapeutic target to treat cancer.leotide; NAM, Nicotinamide;
inoma
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Cancer is a leading cause of deathworldwide, and the second cause
of death in the United States after heart disease [1]. Despite advances
in technology and improved therapeutic approaches to treat this
devastating disease, shortcomings remain, especially in treating
aggressive and metastatic disease and in predicting individualresponses to treatment. These observations underscore the complex-
ity of this disease and the need for personalized cancer therapy to
increase the efﬁcacy of treatment in individual cancer patients [2].
Therefore, discovering new pathways that regulate cancer processes
is crucial to developing better approaches for cancer prevention
and treatment.
The study of sirtuins (SIRT1–7) in cancer tumorigenesis and
therapy is an exciting and promising new area in cancer research [3,4].
SIRT3 is of particular interest. It regulates both cell death and survival,
and therefore, a controversy has emerged in the literature about its
role as a tumor promoter and/or tumor suppressor. In this review, we
will explore the controversy to provide the reader with a better
understanding of the factors that contribute to this issue, and to
discuss future directions and the possibility of using SIRT3 as a novel
therapeutic target to treat cancer.
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Sirtuins (SIRT1–7) are the mammalian homologues of the silent
information regulator 2 (Sir2) ﬁrst discovered in Saccharomyces
cerevisiae as an NAD+-dependent histone deacetylase (HDAC). They
are classiﬁed as class III HDACs: they require NAD+ as a cofactor to exert
their biological function. They contain an evolutionarily conserved core
domain, which is essential for their activity as NAD-dependent
deacetylases or ADP-ribosyltransferases [5,6]. Sirtuin biology is complex,
andsirtuins arewidely expressed innormal tissues [7]. Theyare involved
in a myriad of cellular and tissue functions, such as regulating oxidative
stress, repairing DNA, increasing genomic stability, and affecting cell
survival, apoptosis, development,metabolism, aging and longevity [3,4].
Some sirtuins are located in different cellular compartments (Fig. 1).
Those in the same compartment, such as themitochondrial SIRT3, 4, and
5, have different sequences and thus unique and diverse cellular
functions and can interact with different targets [4–6].
SIRT1 is the best-characterized member of the mammalian
sirtuins. It is located predominately in the nucleus and modulates
cellular stress and survival by deacetylating p53 [8,9], FOXO, and Ku70
[10,11], thus promoting tumorigenesis. SIRT1 is thought to have a role
in skin, colon, breast and lung cancers, via one or more of these
mentioned targets [12–16]. It also regulates vascular endothelial
homeostasis, thereby controlling angiogenesis and vascular function
[17]. Thus, it is likely crucial in regulating cell survival, and its
functions may contribute to cancer tumorigenesis.
On the other hand, SIRT1 might be a tumor suppressor [18–20]. For
example, SIRT1 mutant mice possess an impaired DNA repair response,
genomic instability, and increased incidence of tumorigenesis. Moreover,
SIRT1 levels were lower in breast cancer and hepatic cell carcinoma than
in normal controls [19]. These studies highlight the discrepancy in the
literature about the biological functions of SIRT1 and underscore the
complexity of sirtuin biology (see review by Deng et al. [21]).Fig. 1. Sirtuins subcellular localization: SIRT1 is predominantly located in the nucleus,
are mitochondrial proteins, but SIRT3 may also be found in the nucleus and cytosol
nucleolus, respectively.SIRT2 is found in the cytosol, where it colocalizes with microtu-
bules and deacetylates α-tubulin [22]. It controls cell-cycle progres-
sion [23] and is downregulated in human gliomas, suggesting a tumor
suppressor role in brain cancer [24].
The gene for the nuclear protein SIRT6 is located on chromosome
19p13.3; a region frequently affected by chromosomal alterations in
acute leukemia [25]. In addition, SIRT6-deﬁcient mice possess an
aging-like phenotype and genomic instability [26,27].
SIRT7, which is localized in the nucleolus and functions as a
positive regulator of RNA polymerase I-mediated transcription, is
required for cell proliferation and survival [28]. It is located on
chromosome 17q25.3; a region frequently associated with chromo-
somal alterations in leukemias and lymphomas [29]. SIRT7 is also
upregulated in breast and thyroid cancers [30–32].
The remaining three sirtuins, SIRT3, SIRT4, and SIRT5, are mitochon-
drial sirtuins [7,33]. Although SIRT4 lacks deacetylation activity, it has
weak ADP-ribosyltransferase activity [34,35] and plays an important role
in insulin regulation [36]. SIRT4 knockout mice are viable, fertile, and
display no phenotype abnormalities, compared to wild-type littermates,
but show increased levels of insulin secretion [34]. In contrast to SIRT1and
SIRT3, SIRT4 activity is downregulated by calorie restriction (CR) [34].
SIRT5 has less deacetylase activity than SIRT1–3 [37] and remains the
least-characterized sirtuin. SIRT5 is located on chromosome 6p23, an area
linked to numerous abnormalities associated with malignant diseases,
such as acute myeloid leukemia [38]. In contrast to SIRT4- and SIRT5-
deﬁcient mice, SIRT3-deﬁcient mice show greater mitochondrial hyper-
acetylation than wild-type mice, suggesting that SIRT3 is a key
mitochondrial deacetylase [39].
3. SIRT3 subcellular localization
Determining SIRT3's subcellular localization is important for
ﬁnding its targets and substrates, explaining its cellular functions,and also in the cytosol. SIRT2 is localized in the cytosol. SIRT3, SIRT4, and SIRT5
under different cellular events. SIRT6 and SIRT7 are localized in the nucleus and
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Human SIRT3 is expressed as a full-length 44-kD protein that is
targeted to the mitochondria by its N-terminal localization sequence
[40]. In the mitochondria, SIRT3 is cleaved via the mitochondrial
matrix processing peptidase (MPP) to a short 28-kD protein, which is
important for SIRT3 enzymatic activity [40,41]. Others reported that
both forms for SIRT3 are enzymatically active [42]. Although most
studies support a mitochondrial localization for SIRT3 [7,39–41,43–
47], others suggest that SIRT3 might be present in the nucleus
[42,47,48]. In addition, Sundaresan et al. reported that, although the
long form of SIRT3 is found in the nucleus, cytoplasm, and
mitochondria, the short form is extensively localized in the
mitochondria, and during cellular stress, levels of both forms are
increased in the nucleus and mitochondria of cardiomyocytes [49].
Despite this controversy, one can conclude that SIRT3 exerts a major
role in the mitochondria and might also have a role in other cellular
compartments [50].
4. SIRT3 and cell survival
Mitochondria contain large numbers of key molecules that
regulate cell survival, death, and metabolic pathways and help to
control the balance between health and disease [4,51,52]. For
example, SIRT3 is critical for maintaining mitochondrial integrity
and function. Along with SIRT4 and SIRT5, SIRT3 is a mitochondrial
sirtuin [33], and SIRT3−/− mice manifest hyperacetylated mitochon-
drial proteins, impaired fatty-acid oxidation, and reduced levels of
ATP [39,53,54]. In an early report supporting a prosurvival role for
SIRT3 in vivo, rodents fasted for 48 h had increased levels of the NAD+
biosynthetic enzyme Nampt in their mitochondria. The activity of
Nampt, a stress and nutrient-responsive protein involved in main-
taining cell viability, is regulated by SIRT3 [55]. In addition, under
genotoxic stress, mitochondrial SIRT3 and SIRT4 were required to
protect against genotoxic cell death in human embryonic kidney
(HEK293) and ﬁbrosarcoma cell lines [55].
With its central role in mitochondrial biology, SIRT3 contributes to
cell survival by modulating oxidative stress pathways. Benigni et al.
demonstrated that knockout of the angiotensin II type 1 receptor, a
gene responsible for promoting high blood pressure and various
pathological conditions, such as heart, kidney and brain diseases,
promoted longevity in mice [56]. This receptor knockout was
associated with increased numbers of mitochondria, attenuation of
oxidative stress, and upregulation of Nampt and SIRT3 levels. SIRT3
protects cardiomyocytes and HeLa cells from genotoxic and oxidative
stress-mediated cell death. By binding to and deacetylating Ku70,
SIRT3 augments Ku70–Bax interactions, prevents Bax translocation to
the mitochondria, and prevents apoptosis during stress-mediated
conditions [49]. In addition, SIRT3 protects the heart from cardiac
hypertrophy, at least in part, by attenuating reactive oxygen species
(ROS) [57] and/or by regulating the mitochondrial permeability
transition pore (mPTP) via deacetylating Cyclophilin-D [58]. SIRT3
utilizes exogenous NAD+ to block cardiac hypertrophy by activating
the LKB1–AMP kinase pathway [59] (See review by Pillai et al. [60]).
Under CR conditions, SIRT3 deacetylates and activates superoxide
dismutase 2 (SOD2), thus protecting cells from ROS-mediated cell
damage [61]. SIRT3 also mediates deacetylation of the evolutionarily
conserved lysine 122 needed for the activity of manganese superoxide
dismutase (MnSOD) in response to oxidative stress, thus protecting
cells from stress-mediated damage [62]. Furthermore, in neurons,
SIRT3 acts as prosurvival factor, thus protecting neurons from
excitotoxic injury such as N-methyl-D-aspartate (NMDA)-induced
neuronal death [63].
SIRT3 also exerts a prosurvival role in multiple cancer pathways.
The tumor suppressor, p53 was recently identiﬁed as a new target for
SIRT3 deacetylation in bladder cancer [64]. SIRT3 rescued p53-
induced growth arrest in human bladder tumor-derived EJ-p53cells, supporting a prosurvival role for SIRT3 [64]. Ashraf et al.
reported that increased transcriptional levels of SIRT3were associated
with lymph node-positive breast cancer, and SIRT3 expression was
signiﬁcantly higher in these samples than normal breast biopsies [30].
We recently reported that SIRT3 levels were signiﬁcantly higher in
oral squamous cell carcinoma (OSCC) cell lines and human OSCC
tissue microarray samples (TMAs) than in normal controls [65].
Furthermore, SIRT3 downregulation inhibited cell growth and
proliferation and increased the sensitivity of OSCC cells to radiation
and chemotherapy treatments. To further demonstrate the role of
SIRT3 in oral cancer carcinogenesis in vivo, we used a ﬂoor-of-mouth
oral cancer murine model that mimics human OSCC [66,67] to study
the effect of SIRT3 downregulation on OSCC tumor growth in
immunodeﬁcient mice. Downregulating SIRT3 reduced tumor burden
in vivo, implicating a prosurvival role for SIRT3 in oral cancer [65].
Anoikis, apoptotic cell death triggered by loss of extracellular
matrix (ECM) contacts, is dysregulated in many chronic debilitating
and fatal diseases, including cancer, and resistance to anoikis
contributes to the development and progression of cancer [68–70].
We recently reported that anoikis activates a CD95/Fas-mediated
signaling pathway regulated by receptor interacting protein (RIP), a
kinase that shuttles between CD95/Fas-mediated cell death and
integrin/FAK-mediated survival pathways in oral squamous cell
carcinoma (OSCC) cells [69]. Interestingly, we found that, as OSCC
cells become resistant to anoikis, their SIRT3 expression increases and
their RIP expression decreases. These cells exhibit a greater tumor
burden in vivo. Additionally, SIRT3 is highly expressed in OSCC tissues
and cells, where its expression pattern is opposite to that of RIP
expression (Kapila lab; unpublished data). Thus, these observations
suggest that SIRT3 may play a role in mediating anoikis resistance and
tumorigenesis.
In summary, SIRT3 promotes survival and protects several cell
types from cellular damage by maintaining mitochondrial integrity
and functions and by enhancing their resistance to stress-mediated
cell death. Similarly, SIRT3 overexpression in cancer cells promotes
survival signals while suppressing apoptotic signals, thereby enhanc-
ing tumorigenesis (Fig. 2).
5. SIRT3, apoptosis, and cell death
In contrast, other reports support a proapoptotic role for SIRT3.
SIRT3 induces growth arrest and apoptosis in several colorectal
carcinoma and osteosarcoma cells and in non-cancer human cell
lines, such as retinal epithelial and lung ﬁbroblast cells [71]. This
action is mediated, in part, by SIRT3 modulation of the JNK2 signaling
pathway in these cell lines [71]. Interestingly, the same group
reported earlier that SIRT1 and JNK2 function as constitutive
suppressors of apoptosis in colorectal carcinoma [72]. Thus, SIRT1
and SIRT3 have opposite roles in colorectal carcinoma. A similar
observation was made in neurons [73], however, the role of SIRT3 in
neurons is still controversial [63]. In leukemia cell lines, treatment
with Kaempferol, a ﬂavonoid that auto-oxidizes and generates ROS,
induces apoptosis via increasing Bax and SIRT3 levels and activating
caspase-3 cascades [74].
Recently, SIRT3 was reported to suppress tumors. Kim et al.
implanted SIRT3−/− mouse embryonic ﬁbroblasts (MEFs) expressing
Myc/Ras into the hind limbs of nude mice. After 3 weeks, these mice
developed tumors, but mice implanted with SIRT3+/+ Myc/Ras,
SIRT3−/− Myc, or SIRT3−/− Ras MEFs did not. Importantly, SIRT3
knockout MEFs did not undergo spontaneous immortalization or
possess a tumorigenic phenotype, unless they became immortalized
by the action of Myc or Ras. This transformation-permissive
phenotype was mediated by increased levels of ROS, chromosomal
instability, and altered intracellular metabolism. Some SIRT3−/−mice
developed mammary tumors over the 24-month observation period.
In addition, SIRT3 expression was found to be decreased in
Fig. 2. SIRT3 diverse cellular functions. (Rt) The role of SIRT3 in survival, cell protection, and tumor promotion. Nicotinamide phosphoribosyltransferase (Nampt), a stress and
nutrient-responsive gene, protects against genotoxic cell death via SIRT3 upregulation. Gene knockout (KO) of Ang II promotes longevity in mice either directly or indirectly through
Nampt or SIRT3 upregulation. SIRT3 deacetylates Ku70, augmenting Ku70–Bax interaction, thus attenuating apoptosis and promoting cell survival in cardiomyocytes. In the heart,
SIRT3 also prevents cardiac hypertrophy by attenuating reactive oxygen species (ROS), deacetylating cyclophilin-D, and activating the anti-hypertrophic LKB1-AMP kinase signaling
pathway. Calorie restriction (CR) prevents aging and age-related diseases by augmenting SIRT3 levels and functions in the cell, at least in part, by deacetylating and activating
superoxide dismutase 2 (SOD2), thus protecting the cell from ROS-induced cell death. In addition, ionizing radiation (IR) in normal cells may enhance SIRT3-deacetylated-MnSOD
activation, therefore, again protecting the cell from ROS-induced cell death. Although it is still controversial, in neurons SIRT3 seems to protect cells from excitotoxic injury such asN-
methyl-D-aspartate (NMDA)-induced neuronal death. SIRT3 deacetylates p53, attenuating p53-BAG2 complex stability (BAG2; BCL2-associated athanogene 2), thus decreasing
apoptosis. Lymph node-positive breast cancer is associated with increased levels of SIRT3. SIRT3 is also overexpressed in oral cancer and in anoikis-resistant oral squamous cell
carcinoma (OSCC) cells, thus promoting OSCC cell survival and preventing anoikis-mediated cell death. (Lt) The role of SIRT3 in apoptosis, cell death, and tumor suppression. In
colorectal carcinoma, Bcl-2 knockdown (KD) was associated with SIRT3 upregulation and apoptosis by deacetylating AceCS2 and switching on the JNK2 signaling pathway. In
neurons, low potassium (LK)-induced apoptosis is mediated by SIRT3. In leukemia, the treatment with Kaempferol, a ﬂavonoid that auto-oxidizes and generates ROS, induces
apoptosis by SIRT3 and Bax upregulation, thus switching on caspase-3 cascades and apoptosis. SIRT3 is downregulated in human breast cancer cells compared to normal controls,
and SIRT3−/−mice developed mammary tumors over a 24-month period. In human colon carcinoma and osteosarcoma cells, SIRT3 also works as a tumor suppressor by suppressing
ROS and HIF1-α. In HEK-293 cells, the transient receptor potential melastatin-related channel 2 (TRPM2), a nonselective cation channel induces cell death in response to oxidative
stress via SIRT3.Unlike non-transformed cells, in some cancer cells, SIRT3 deacetylates cyclophilin-D, inducing the dissociation of hexokinase II/VDAC complex in the mitochondria,
thus activating apoptosis.
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other cancers (glioblastoma, prostate, head and neck, and others),
based on a review of gene expression data from other sources [75].
These ﬁndings suggest that SIRT3 is a tumor suppressor. In agreement
with this report, others found that, in breast cancer patients, SIRT3
levels were lower or undetectable in most of the samples than in
normal individuals, and speciﬁcally breast and ovarian cancers were
frequently associated with focal deletion of the SIRT3 gene. Addition-
ally, tumors lacking SIRT3 (SIRT3-KO-MEFs transformed with Ras and
E1a oncogenes) grew faster and were bigger than transformed SIRT3-
WT tumors in a xenograft model. This downregulation was associated
with upregulation of hypoxia inducible factor-1 α (HIF1-α) targeted
genes [76]. Similarly, Bell et al. also demonstrated a tumor suppressor
role for SIRT3 in human colon carcinoma and osteosarcoma cells, via
the ability of SIRT3 to negatively regulate ROS and HIF1-α [77].
In HEK-293 cells, the transient receptor potential melastatin-
related channel 2 (TRPM2), a nonselective cation channel, confers
susceptibility to cell death in response to oxidative stress. This cell
death was reduced by treating with the general sirtuin chemical
inhibitor, NAM, and with selective downregulation of both SIRT3
and SIRT2 [78], thus supporting a proapoptotic role for these sirtuins
in the context of TRPM2 and oxidative stress. SIRT3 also deacetylates
cyclophilin D, a protein required for hexokinase II binding to
voltage-dependent anion channels (VDACs) to maintain mitochon-
drial integrity. Thus, in some cancer cells, SIRT3 induces hexokinase
II to dissociate from the mitochondria and activate apoptosis.
However, in non-transformed cells, activation of SIRT3 may prevent
necrotic cell death [79]. From these ﬁndings, SIRT3 seems to
function as a proapoptotic signal in some cancer and non-cancer
cell lines, and it may prevent a transformation-permissive pheno-type in certain normal cells, thus guarding the cell as a tumor
suppressor (Fig. 2).
6. SIRT3, metabolism, and cancer
Metabolism is important in cancer development and prevention
[80]. Cancer cells are metabolically active and need ATP to maintain
their growth, proliferation, and survival [81,82]. Thus, understanding
how speciﬁc regulators of metabolism are altered in cancer will be
very helpful for developing therapies. Furthermore, cancer cells shift
their mode of ATP/energy production from oxidative phosphorylation
to glycolysis. This is called the “Warburg effect” [83,84]. However,
cancer cells can switch between glycolysis and fatty acid oxidation,
depending on the environment and substrate availability. This
suggests that targeting one metabolic pathway may not be sufﬁcient
as a treatment strategy, since this may lead to resistance and more
aggressive cancer phenotypes [85,86].
Mitochondria are important determinants of energy regulation,
metabolic homeostasis, and cellular lifespan [52,87,88], and in the
mitochondria, SIRT3 regulates numerous metabolic processes, such as
fatty-acid oxidation, oxidative phosphorylation, and the TCA cycle.
These observations implicate SIRT3 as a key regulator of cancer
processes. Several studies have highlighted the role of SIRT3 in
metabolism and homeostasis and revealed new targets and substrates
for SIRT3-dependent deacetylation [33,89]. However, few linked
SIRT3-regulated metabolism to cancer. Those that addressed SIRT3
as a tumor suppressor demonstrated that SIRT3−/− mice have
depleted levels of ATP: about 50% less in the heart, liver and kidney,
and increased ROS production than in wildtype mice [54,75]. Indeed,
increased ROS levels promote mutagenesis and genomic instability
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SIRT3 critically regulates the Warburg effect. Thus, SIRT3 mediates
metabolic destabilization of HIF1-α, a factor that regulates the
metabolic shift to glycolysis in cancer cells, and its upregulation is
associated with tumorigenesis [76,77].
SIRT3 regulates mitochondrial energy homeostasis. More specif-
ically, it maintains ATP basal levels by regulating mitochondrial
electron transport by deacetylating the 39-kD protein NDUFA9 [54]
and succinate dehydrogenase [91]. Moreover, ATP synthase (ATP5A)
and the chaperone protein HSP70, which protect against oxidative
stress, are targets for SIRT3 [92]. SIRT3 also regulates fatty-acid
oxidation by deacetylating long-chain acyl coenzyme A dehydroge-
nase (LCAD), thereby augmenting its enzymatic activity. Mice lacking
SIRT3 have hyperacetylated LCAD and fatty-acid oxidation disorders
during fasting, including reduced ATP levels, hypoglycemia, and cold
intolerance [53]. SIRT3 downregulation in the hepatocyte cell line,
HepG2, results in dysfunction in the electron transfer chain, reduction
of mitochondrial membrane potential, and increased levels of ROS
[47]. The ﬁrst discovered target of SIRT3-mediated deacetylation was
acetyl-CoA synthetase 2 (AceCS2). SIRT3 deacetylates and activates
AceCS2, an enzyme important in converting acetate to acetyl-CoA in
the presence of ATP and CoA, an enzyme required for TCA (Krebs)
cycle initiation [93–95]. Since SIRT3 also modulates several enzymes
of the TCA cycle, including isocitrate dehydrogenase 2 (IDH2), this is
yet another mechanism by which SIRT3 helps to modulate energy
production from carbohydrates, fats, and proteins [96]. In addition,
under CR conditions, SIRT3 seems to modulate IDH2 function and
protect the cell from oxidative stress-induced cell death [97].
Interestingly, mutations of IDH2 are associated with some cancer
types, such as gliomas and acute myeloid leukemias; however, the use
of IDH2 as a potential therapeutic target is still controversial [98–100].
Shi et al. demonstrated that SIRT3 regulates thermogenesis by
modulating mitochondrial proteins, such as peroxisome proliferator-
activated receptor gamma coactivator-1alpha (PGC-1α) and the
uncoupling protein 1 (UCP1) [44]. On the other hand, SIRT3 is a
target for PGC-1α, whereby ROS levels are regulated in the cell [101].
PGC-1α itself has important metabolic roles, including regulating
adaptive thermogenesis, gluconeogenesis, mitochondrial biogenesis,
and respiration, and it protects cells against ROS generation and
damage. PGC-1α binds to the SIRT3 promoter, enhancing its
expression and downstream signaling pathways, including the
activation of anti-oxidants SOD2 and catalase [101].
Moreover, SIRT3 levels are lower in obese mice than in normal
littermates, thus implicating a role for SIRT3 in controlling obesity
[44]. Additionally, ob/ob mice treated with leptin, a key hormone in
regulating fat metabolism and energy expenditure, showed increased
levels of SIRT3, further supporting a role for SIRT3 in controlling
obesity [102]. SIRT3 regulates ketone body production during fasting
via deacetylating the mitochondrial protein 3-hydroxy-3-methylglu-
taryl CoA synthase 2 (HMGCS2) [103], providing further evidence of
the important roles of SIRT3 in regulating cellular metabolism.
In aggregate, although few studies have linked SIRT3-mediated
metabolism directly to cancer, all these studies support a role for
SIRT3 as a critical regulator of metabolism in the mitochondria, which
in turn, participates in cancer development or prevention. Addition-
ally, age-related diseases share common risk factors and perhaps even
redundancy in their mechanisms of pathology [104]. Therefore,
determining the role of SIRT3 in those diseases may help better
deﬁne its potential role in their etiology and in the development of
novel therapeutics.
7. Is SIRT3 a tumor promoter or suppressor?
Cancer cells possess six common traits including self-sufﬁciency in
growth signals, insensitivity to antigrowth signals, evading apoptosis,
sustained angiogenesis, limitless replicative potential, and tissueinvasion and metastasis [105]. In addition, emerging hallmarks and
enabling characteristics in cancer cells include dysregulation of
cellular energy and avoidance of immune distraction, and the
consequences of genomic instability and tumor-promoting inﬂam-
mation are factors that contribute to creating a tumorigenic
microenvironment, thus further facilitating and supporting the
unique features of cancer cells' phenotype [82]. The fact that SIRT3
can regulate most of these cancer processes, implicates SIRT3 as a
novel potential therapeutic target to treat cancer. However, the
discrepancy in the literature regarding the role of SIRT3 in cancer
complicates how best to develop SIRT3 as a potential target for cancer
therapy. It may be most appropriate to consider the cell-dependent
context, the background of each cell line tested, and the inﬂuence of
different dysregulated pathways in these cell lines, as in the case for
SIRT1 in colon cancer [14].
The ﬁnding that SIRT3 is overexpressed in metabolically active
tissues, such as the heart, where SIRT3 protects against genomic and
stress-mediated apoptosis, at least in part, via ROS reduction and
increases in Ku70–Bax interactions [49,57], is one mechanism by
which cancer cells that overexpress SIRT3 similarly resist cell death.
This was indeed demonstrated by the same group in the HeLa cervical
cancer cell line [49].
SIRT3 is overexpressed to a greater extent in several human oral
cancer cells and tissues than in normal controls, and SIRT3 down-
regulation in these cells inhibited OSCC cell growth and proliferation
and enhanced radio- and chemo-therapeutic drug cytotoxicity. These
observations suggest that these cells rely on SIRT3 signaling for
survival. In addition, SIRT3 downregulation in OSCC cells in vivo
reduced tumor burden in mice [65], further underscoring the critical
role of SIRT3 in promoting survival and tumorigenesis in OSCC.
Moreover, under suspension conditions, oral cancer cells aggregate to
become anoikis resistant, maintaining their survival signals to escape
suspension-induced cell death. One of those survival signals seems to
be mediated by increased SIRT3 expression levels (Kapila lab,
unpublished data).
Nampt protection against cell death, which was dependent on
SIRT3 expression in ﬁbrosarcoma cells [55], and the ability of SIRT3
overexpression to rescue p53-induced cell growth arrest in human
bladder cancer [64], also demonstrate a prosurvival role for SIRT3 in
these tumors. Overexpression of SIRT3 in lymph node-positive breast
cancer, implicates a role for SIRT3 in advanced stages of breast cancer
[30]. Together, these ﬁndings support a prosurvival role for SIRT3 in
cancer, and the concept that SIRT3 functions as a tumor promoter in
these tumors.
In contrast to the ﬁndings of Ashraf et al. [30], others showed that
SIRT3 levels were lower in human breast cancer samples than in
normal controls, and SIRT3 levels were further downregulated in
advanced stages of breast cancer, supporting an opposite role for
SIRT3 in breast cancer [75,76]. Interestingly, Kim et al. showed that
MEFs from SIRT3 knockout mice did not become immortalized
spontaneously. Instead, they required at least one oncogenic hit with
either Myc or Ras to become immortalized in vitro and both Myc and
Ras to develop tumors in vivo[75]. This suggests that environmental
or genetic factors control how SIRT3 functions in cells. In addition,
this group found that seven out of twenty SIRT3 knockout mice
developed mammary tumors over a 24-month period, while none of
the SIRT3 wildtype mice developed tumors [75]. However, after
abrogating the function of an important cellular regulator such as
SIRT3, 24 months is a reasonable time for genomic alterations and
mutations to accumulate, which are critical initiating factors in the
multistep process of cancer development [106,107]. Additionally,
since SIRT3 is a critical regulator of the Warburg effect in cancer
cells, downregulation of SIRT3, such as in breast cancer, would be
associated with increased levels of ROS and a shift in metabolism
toward glycolysis via the upregulation of HIF1-α and its targeted
genes [76]. Moreover, in human colon carcinoma and osteosarcoma
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colon carcinoma cells with stable knockdown of SIRT3 demonstrated
enhanced tumorigenesis in a xenograft model, and augmented
HIF1-α protein stability and transcriptional activity compared to
controls [77].
In contrast, tumors with high levels of SIRT3 as part of their
genomic and signaling dysregulation could take advantage of this
overexpression to sustain their survival signals by downregulating
ROS levels and maintaining high amounts of ATP/energy sufﬁcient for
their cancer cell machinery. In this regard, reduced levels of ROS were
associated with higher levels of antiapoptotic mitochondrial proteins,
such as Bcl-2 and Bcl-xL in OSCC cells [108]. Interestingly, ROS
differentially regulates apoptosis and malignant transformation in
several cancer types by regulating Bcl-2 [109,110]. Thus, superoxide
plays a proapoptotic role by downregulating and degrading Bcl-2
proteins by ubiquitination, whereas nitric oxide (NO)-mediated S-
nitrosylation of Bcl-2, abrogates its ubiquitination and subsequent
proteosomal degradation [109,110]. In addition, Bcl-2 family proteins
have been linked to resistance to cancer therapy in B-cell lymphomas
and oral cancer [111–113]. It would be interesting to study the role of
SIRT3 in modulating Bcl-2 family proteins in these cancer cell types.
Interestingly, SIRT1 is overexpressed in drug-resistant cancer
cells, including neuroblastoma, osteosarcoma, mammary, and
ovarian carcinomas [114]. Similarly we found that two OSCC cell
lines (UM-SCC-1 and UM-SCC-17B) that are highly resistant to
radiation and cisplatin treatment [115,116] become sensitive to low
doses of both treatments only when SIRT3 levels were down-
regulated. This suggests a role for SIRT3 in resistance-mediated
mechanisms in oral cancer. This resistance could be mediated by
regulating Bcl-2 family proteins or related signaling cascades via
SIRT3-ROS modulation. These mechanisms are currently under
investigation in our laboratory.
Additionally, depending on SIRT3 levels, current evidence suggests
that SIRT3 controls mitochondrial ROS directly or indirectly in the cell
[60,89], thereby dictating the fate of a given cell type. Therefore, a cell
either undergoes damage and assumes an environmentally-permis-
sive neoplastic phenotype [62,75,76,117] or a protective/stress-
mediated resistance and undergoes cell survival [49,57,61,62,97].
Interestingly, contrasting ﬁndings highlight the dichotomy of
SIRT3's role in cancer processes in different cancer cell types. We
found in oral cancer and others found in ﬁbrosarcoma, cervical cancer,
and bladder cancer that SIRT3 was required to protect these tumors
from stress-mediated cell death by various stimuli [55,57,64,65].
Others showed that SIRT3 was required to suppress tumorigenesis,
and to induce stress-mediated cell death in tumors, including
colorectal carcinoma, osteosarcoma, leukemia, and breast cancer
[71,74–77]. Furthermore, the recent ﬁndings that SIRT3 might
deacetylate cyclophilin-D, resulting in either enhancing apoptosis in
transformed cells such as HeLa cells [79] or promoting survival and
protecting against age-related cardiac hypertrophy [58], clearly show
that SIRT3 may function differently depending on cell type. Even in
normal cells such as neurons, SIRT3's role also seems to be
controversial [63,73].
Thus, SIRT3's function varies in different normal and tumor tissues
and may be cell- and tumor-type speciﬁc. Its role must not be
generalized, but should be examined in each cancer type separately to
determine whether it functions as a tumor promoter or suppressor.
More importantly, the genetic or epigenetic alterations that underlie
cancer initiation and progression may differ from individual to
individual even within the same cancer type, resulting in a
dysregulation of different signaling cascades that may or may not
depend on SIRT3. These issues complicate our ability to predict the
importance of SIRT3 in a given carcinogenic event. Therefore, looking
at the bigger picture by screening cancer patients to analyze their
genomic, epigenomic, proteomic, and metabolomic proﬁle will help
discover the dysregulated pathways that lead to a given disease, andthereby help maximize and personalize the therapeutic approaches
for each patient.
8. Sirtuins as potential therapeutic targets for cancer
Several studies have implicated sirtuins as novel therapeutic
targets for many age-related diseases, including cancer, but how
sirtuins are involved in cancer is still not clear and is controversial. In
this review, we want to highlight the discrepancies in the literature
about the roles of sirtuins in cancer, especially those of SIRT1 and
SIRT3. A clear understanding of how individual sirtuins are involved
in different cancer types is important for assessing their potential in
possible therapies. Sirtuins seem to be involved in tumorigenesis, and
thus, sirtuin inhibitors/modiﬁers might have therapeutic beneﬁt.
Several inhibitors and activators of sirtuins have been tested in
different cancer cell lines, but few have been tested in vivo[51]. The
sirtuin inhibitors, sirtinol and splitomicin, induced senescence-like
growth arrest in breast and lung cancers [118]. NAM, another sirtuin
inhibitor, induced apoptosis in lung cancer [8]. We demonstrated
that sirtinol and NAM inhibited cell growth and proliferation and
induced apoptosis in oral cancer cells [65]. Treatment of B-cell
lymphoma cells with cambinol, a SIRT1 inhibitor, inhibited tumor cell
growth and induced apoptosis in vitro, and reduced tumor size
compared to controls in vivo[119]. Moreover, cambinol sensitized
lung cancer cells to the DNA-damaging agent etoposide, thus
inducing cell death and etoposide-induced cell-cycle arrest [119]
(see review by Balcerczyk et al. [120]).
Resveratrol, a polyphenol phytoalexin and natural component
found in the skin of red grapes and red wine, works as an activator of
sirtuins and possesses diverse natural therapeutic beneﬁts, including
cardiac protection, anti-inﬂammatory and anti-carcinogenic effects,
preventing obesity, and promoting longevity [121,122]. These
therapeutic beneﬁts seem to work, at least in part, by activating
SIRT1 and SIRT3, although it is not yet clear whether these effects are
mediated by direct or indirect mechanisms [121–124]. Interestingly,
resveratrol modulates both survival and death signals, depending on
the administered dose in vivo[125]. At low doses (2.5 or 5 mg/kg for
14 days in rats), resveratrol provided cardiac protection and lower
levels of apoptosis than controls. In contrast, at high doses (25 or
50 mg/kg), resveratrol hindered cardiac function and promoted
apoptosis of cadiomyocytes. The former effect was mediated by
augmenting survival signaling pathways, including p-Akt, NFκB, and
Bcl-2 activation. The latter was mediated by switching on the death
program by repressing the same pathways [125]. Moreover, resver-
atrol is the most studied sirtuin activator in cancer prevention. Many
studies have shown resveratrol to be a natural anticarcinogenic agent,
modulating different stages of cancer, including initiation, promotion,
and progression in neuroblastoma, hepatoma, breast, lung, pancreatic,
and prostate cancers in vitro or in vivo[126,127]. However, many of
these studies yielded contradictory results even in the same tumor
type. We reasoned that these discrepancies could be due to the
different experimental approaches used to examine resveratrol. For
instance, some data were collected from mice and others from rats.
Some studies used animal carcinogenesis models with different
genetic backgrounds, others used different doses of resveratrol, and
yet others used different time frames for drug administration.
Resolving these discrepancies would be very helpful. In addition,
these drugs are all generalized inhibitors or activators of several
sirtuin family members. Thus, some redundancy or even opposing
actions of some sirtuin functions may be expected. Furthermore,
different tumors have different genetic backgrounds that differ from
one person to another. This diversity may explain why one patient
responds well to a speciﬁc treatment but another patient with the
same type of cancer does not.
The rapidly evolving era of personalized medicine holds great
promise for the future of cancer therapy. For example, the use of RNA
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may be useful especially in combination with conventional treat-
ments. Currently, studies using RNAi are still in early stages of clinical
trials. RNAi has been tested in different types of cancer, such as lung,
advanced liver, and chronic myeloid leukemia. We recently used an
OSCC ﬂoor-of-mouth model in which mice treated with shRNA-
modiﬁed-OSCC cells to reduce SIRT3 levels had a lower tumor burden
than controls [65]. This demonstrates the usefulness of targeted gene
knockdown as a potential therapeutic approach (see review by Phalon
et al. [128]).
Class-I and II HDAC inhibitors have been tested in phase-I and II
clinical trials with or without conventional chemotherapeutic drugs.
The agents were well tolerated with low toxicity and yielded
promising results. Some of the agents used include phenyl acetate,
suberoylanilide hydroxamic acid, and Trichostatin to treat patients
with solid tumors, hematologic malignancies, and advanced leuke-
mias [129]. To our knowledge, there are no published reports on
clinical trials using class-III HDAC inhibitors of sirtuins to treat cancer.
However, class-III HDAC activators of sirtuins such as resveratrol are
currently in early stages of clinical trials, and have been tested for
safety and potential treatment of age-related diseases such diabetes,
neurodegenerative disorders and cancer (see references [130,131]
about ongoing and published clinical trials).
9. Conclusions
We are just beginning to appreciate the role of sirtuins in treating
age-related diseases, such as cancer. However, the current controver-
sy regarding the role of SIRT3 in cancer, emphasizes the importance of
examining this area further. Data support that SIRT3 can function as a
tumor promoter or suppressor, depending on the cell- and tumor-
type and the presence of different stress or cell death stimuli. Also,
genetic and environmental factors underlying cancer initiation and
development in each patientmay contribute to this discrepancy. Thus,
it is important to carefully examine the role of SIRT3 in each tumor
type separately and in both in vitro and in vivo settings. Understanding
the mechanistic differences in tumor types will enhance our
knowledge of the complex biology of sirtuins in cancer and,
ultimately, help us develop better therapeutic approaches. Therefore,
screening cancer patients for genomic, proteomic, and metabolomic
abnormalities and dysregulated signaling cascades to highlight
important alterations might help identify useful targets for person-
alized cancer therapy and more successful cancer treatment.
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